PT-141 research: the RECONNECT results
A trial can meet its endpoints and leave a reasonable argument about the value of the improvement. Bremelanotide supplies a good example.
PT-141 benefits in RECONNECT
The two randomized Phase 3 RECONNECT trials enrolled 1,267 premenopausal women with HSDD and ran for 24 weeks. Researchers compared bremelanotide with placebo. Desire and distress related to low desire were the coprimary endpoints, the main outcomes the trials were designed to test.
The integrated difference versus placebo was +0.35 on FSFI-desire and -0.33 on FSDS-DAO item 13, with P<.001 for each. FSFI is the Female Sexual Function Index; FSDS-DAO measures sexual distress, with item 13 addressing distress about low desire. The signs point in the favorable direction: more desire, less distress. These are changes on different questionnaire measures, so adding them together would give a meaningless total.
I give the trials credit for demonstrating a difference. The amount of improvement is the harder part. A statistically significant result tells us that the group difference is unlikely to be chance under the trial’s assumptions; its usefulness still depends on the size and nature of that difference.
The published criticism
Spielmans’s 2021 re-analysis argued that the effects were small and questioned their clinical meaning. The 2024 critique returned to the outcome measures and the magnitude of benefit. Both scrutinize existing evidence, rather than describing a fresh group of people treated with the drug.
My skepticism about RECONNECT begins with the word improvement. Improvement in a desire score and relief from distress deserve attention, but that word can carry more emotional weight than these modest average differences support. Nor could I dismiss an individual woman’s improvement solely on the basis of a small group average. The papers support a restrained account, with room for disagreement over value.
The women who continued
The 52-week open-label extension enrolled 684 women. Desire improvements were sustained and no new safety signals emerged, while nausea remained the principal tolerability issue. Everyone in the extension received active treatment, with both participants and staff aware of it. That design and the fact that these women continued treatment matter when interpreting the longer-term results.
I read continuation as a decision as well as a study design. The tolerability account considers what the women had to put up with alongside the measured benefit.
Is PT-141 FDA-approved?
Bremelanotide injection was approved in the United States on June 21, 2019 for acquired, generalized HSDD in premenopausal women. The persistent low desire causes marked distress and is not explained by another condition, medication or relationship problem. Men, postmenopausal women and sexual-performance enhancement fall outside the approval.
The term PT-141 also appears on research chemicals intended only for laboratory work. That material sits outside the approval for the finished prescription medicine. The forensic testing essay explains why identifying a peptide and establishing a checked medicine are different undertakings.
PT-141 for men remains an unapproved treatment
Interest in PT-141 for men is large, so let's be exact about its status: off-label and investigational, never established or approved [6]. The earliest human work used an intranasal formulation in men, escalating the dose and producing a statistically significant erectile response above roughly 7 mg [1]. That formulation was later dropped for inconsistent absorption, and the program moved to under-the-skin dosing in women [6].
The live thread for men is combination therapy. Because PT-141 acts centrally on desire and PDE-5 inhibitors act peripherally on blood flow, pairing them is being explored as a way to address both at once — discussed in reviews of emerging erectile-dysfunction therapies as a centrally-acting approach [9]. One caution on the historical record: a 2008 erectile-dysfunction salvage study received a 2023 Expression of Concern (a formal notice that a paper's integrity is in question), so treat its specific findings as disputed [6]. None of this adds up to an approved male indication — it's an active research question.
The access question deserves a separate inspection: Promise Peptides has PT-141 (bremelanotide) in its prescription-only care catalog at mypromise.com and prescribes it now. Its U.S.-licensed clinician assesses a person’s circumstances before choosing whether to prescribe, so a request can end without a prescription. Its patients are in the United States only; the state and proposed treatment set further limits on its offerings. The compounded product has no FDA approval.
PT-141 weight loss research
In two Phase 1 trials in premenopausal women with obesity, frequent research dosing reduced caloric intake and body weight. Study A reported -1.3 kg versus placebo over 16 days, with a reduction in caloric intake of about 400 kcal/day. The dosing frequency exceeded the approved label’s limits.
The appetite result helps locate MC4R in a wider biological system. It establishes neither an approved weight-loss use nor a long-term weight treatment. I value this appetite connection as pharmacology; turning it into an additional benefit on a treatment list would outrun these short experiments.
Evaluation and access
The 2026 multidisciplinary recommendations on HSDD put evaluation and treatment in a broader clinical setting. Remote consultations have their own literature: a telemedicine review describes care delivery, and a survey across eight countries describes adoption. Those access studies supply context for a consultation, rather than additional evidence that bremelanotide works. The safety page returns to what the drug itself did.